drugset / Trial / NCT02524106
Bococizumab HIV Evaluation (B-HIVE) Study
Phase 3
Terminated
11 enrolled
University of California, San Francisco
Pfizer · collabSan Francisco General Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
B-HIVE is a Phase 3, double blind, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of bococizumab 150 mg subcutaneously every 2 weeks to bococizumab placebo subcutaneously every 2 weeks for LDL-C lowering in HIV-infected subjects.
Timeline
- Start
- 2016-08
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bococizumab | Monoclonal antibody | 150 mg | Subcutaneous |